Literature DB >> 6684226

Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.

U A Besinger, K V Toyka, M Hömberg, K Heininger, R Hohlfeld, A Fateh-Moghadam.   

Abstract

Sixty patients with myasthenia gravis were examined prospectively by measuring serial titers of antibodies against human acetylcholine receptor, and these were correlated with a quantitative clinical score. Serial titers of antibodies detected by the standard immunoprecipitation assay (binding antibodies) correlated with the clinical score in most patients. Antibodies blocking the binding of alpha-bungarotoxin to receptors (blocking antibodies) were detected in 29 patients. Serial blocking antibody titers correlated with changes in muscle weakness less often than binding antibody titers. Titers of both classes of antibodies often followed a divergent course, suggesting that the autoimmune B-cell clones that formed these classes of antibodies may have been activated asynchronously.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684226     DOI: 10.1212/wnl.33.10.1316

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  50 in total

1.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

2.  Progress in the treatment of myasthenia gravis.

Authors:  Ralf Gold; Reinhard Hohlfeld; Klaus V Toyka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

3.  Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.

Authors:  Andrew Chan; De-Hyung Lee; Ralf Linker; Alexander Mohr; Klaus V Toyka; Ralf Gold
Journal:  J Neurol       Date:  2007-08-27       Impact factor: 4.849

Review 4.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 5.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

6.  Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.

Authors:  F Heidenreich; T Jovin
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

7.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

8.  T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits.

Authors:  A A Manfredi; M P Protti; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Antibodies against saline-soluble components of skeletal muscle in myasthenia gravis.

Authors:  A Komiyama; I Kamo; S Furukawa; S Akazawa; K Hirayama; E Satoyoshi
Journal:  J Neurol       Date:  1988-03       Impact factor: 4.849

10.  Widely varying TNF-alpha levels in patients with myasthenia gravis.

Authors:  Jin Soo Lee; In Soo Joo; Jung Im Seok
Journal:  Neurol Sci       Date:  2009-02-13       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.